Study summary · research use only
FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
In this study in aged mice, the authors report that FOXO4-DRI, described as a specific FOXO4-p53 binding blocker, induced apoptosis in senescent Leydig cells and reduced secretion of certain Senescence-Associated Secretory Phenotype factors, which was associated with increased proliferation of cocultured GC-1 SPG cells. Naturally aged mice treated with FOXO4-DRI showed increased sperm quality and improved spermatogenesis compared to untreated aged mice, per the abstract.
Abstract
Male ageing is always accompanied by decreased fertility. The forkhead O (FOXO) transcription factor FOXO4 is reported to be highly expressed in senescent cells. Upon activation, it binds p53 in the nucleus, preventing senescent cell apoptosis and maintaining senescent cells in situ. Leydig cells play key roles in assisting spermatogenesis. Leydig cell senescence leads to deterioration of the microenvironment of the testes and impairs spermatogenesis. In this study, we observed that FOXO4-DRI, a specific FOXO4- p53 binding blocker, induced apoptosis in senescent Leydig cells, reduced the secretion of certain Senescence-Associated Secretory Phenotype and improved the proliferation of cocultured GC-1 SPG cells. In naturally aged mice, FOXO4-DRI-treated aged mice exhibited increased sperm quality and improved spermatogenesis.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.